ADC Therapeutics (NYSE:ADCT) shares jumped 13% premarket on Tuesday after reporting encouraging early results for a combination therapy for patients with relapsed/refractory follicular lymphoma (FL).
In an investigator-initiated Phase 2 clinical trial, Zynlonta (loncastuximab tesirine-lpyl), a CD19-directed antibody drug conjugate, in combination with monoclonal anti-CD20 antibody rituximab led to 96.3% overall response rate and 85.2% complete response rate in r/r FL patients.
After a median follow-up of 9.7 months, the median progression-free survival (PFS) was not reached, and the 12-month PFS was 92.3%.
The data is from a single-institution study conducted at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Based on the initial results, the investigators are planning a multicenter clinical trial to expand the current cohort and decrease the length of therapy to six cycles. The trial is expected to be launched in the first quarter of 2024.
